Patrones de tratamiento con agentes biológicos. Eficacia y sobrevida a largo plazo en pacientes con artritis reumatoidea
Resumen
En nuestro país existen pocos datos acerca de los patrones de tratamiento y la sobrevida de las Drogas Modificadoras de la Artritis Reumatoidea biológicas (DMARb) en pacientes con Artritis Reumatoidea (AR). El objetivo de nuestro estudio fue estimar la sobrevida del 1° y 2° agente biológico, determinar sus causas de suspensión y evaluar factores que influyan en la sobrevida de estos agentes.Citas
I. Brodszky V, Bíró A, Szekanecz Z, Soós B, Baji P, Rencz F, et al. Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. Clinicoecon Outcomes Res 2017;9:139-147.
II. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388(10055):2023-2038.
III. Badley E, DesMeules M (2003) Introduction. In: Badley E, DesMeules M, eds. Arthritis in Canada: an ongoing challenge. Ottawa, Canada: Health Canada. http://www.lupuscanada.org/english/resources/pdfs/Arthritis-in-Canada-Health-Canada.pdf. Accessed 13 September 2013.
IV. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002;41(7):793-800.
V. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58(1):15-25.
VI. Wong R, Davis AM, Badley E, Grewal R, Mohammed M. Prevalence of arthritis and rheumatic diseases around the world: a growing burden and implications for health care needs. In: Models in Care in Arthritis, Bone & Joint Disease (MOCA) http://www.modelsofcare.ca/pdf/10-02.pdf. Accessed 13 September 2013.
VII. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006;36(3):182-188.
VIII. Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 2016;36(5):685-695.
IX. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2013 update. Ann Rheum Dis 2014;73(3):492-509.
X. S aag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59(6):762-784.
XI. S ullivan SD, Alfonso-Cristancho R, Carlson J, Mallya U, Ringold S. Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review. J Med Econ 2013;16(3):391-396.
XII. Wilke T, Mueller S, Lee SC, Majer I, Heisen M. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis. BMC Musculoskelet Disord 2017;18(1):332.
XIII. D u Pan SM, Scherer A, Gabay C, Finckh A. Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis 2012;71(6):997-999.
XIV. Favalli EG, Biggioggero M, Marchesoni A, Meroni PL. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 2014;53(9):1664-1668.
XV. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75(1):3-15.
XVI. Navarro-Millán I, Curtis JR. Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis. Curr Opin Rheumatol 2013; 25(3):384-390.
XVII. Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, León-García M, Emery P, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations 2014;73(3):516-528.
XVIII. R amiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73(3):529-535.
XIX. De la Vega M, Casado G, Citera G, Soriano E, Venarotti H, Saurit V, at al. Primer reporte de eventos adversos de tratamientos biológicos en Argentina. Informe de Registro BIOBADASAR. Rev Arg Reumatol 2011;22(4):40-54.
XX. Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham III C, at al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69(9):1580-1588.
XXI. A letaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23 (Suppl. 39):S100-S108.
XXII. L ars EK, Tore S, Pierre G. The LUNDEX, a new index of drug efficacy in clinical practice: Results of a five‐year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum2006;54(2):600-606
XXIII. Ramiro S, Landewé R, van der Heijde D, Collier D, Michaud K. Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors? RMD Open 2015;1(1): e000155.
XXIV. S oliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70(4):583-589.
XXV. H etland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct Comparison of Treatment Responses, Remission Rates, and Drug Adherence in Patients With Rheumatoid Arthritis Treated With Adalimumab, Etanercept, or Infliximab Results From Eight Years of Surveillance of Clinical Practice in the Nationwide Danish DANBIO Registry. Arthritis Rheum 2010;62(1):22-32.
XXVI. Torrente-Segarra V, Bergstra SA, Salomon-Escoto K, Da Silva J, Veale D, Al-Emadi S, et al. Is current smoking status and its relationship to anti-cyclic citrullinated peptide antibodies a predictor of worse response to biological therapies in rheumatoid arthritis patients? Scand J Rheumatol 2018; doi: 10.1080/03009742.2017.1418423. [Epub ahead of print]
XXVII. Saevarsdottir S, Wedre´n S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, at al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: Observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 2011;63(1):26-36.
XXVIII. Canhão H, Rodrigues AM, Mourão AF, Martins F, Santos MJ, Canas-Silva J, et al. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology 2012;51(11):2020-2026.
XXIX. Bartlett SJ, Schieir O,Valois MF, Hitchon C, Boire G, Haraoui B, et al. Who is not reaching remission in early RA and Why? Predictors for persistent disease activity in the first year differ in men and women and are related to lifestyle and treatment. DOI: 10.1136/annrheumdis-2018-eular.2071
Derechos de autor 2018 Sociedad Argentina de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
